MODERATOR
:
SPEAKER
(S):
Elisabeth Maurer-Spurej, PhD, Chief Technology Officer, LightIntegra Technology Inc
James AuBuchon, MD, FCAP, FRCP (Edin), President & CEO, Puget Sound Blood Center
In Vivo Evaluation of Platelet Systems
Alan Tinmouth, MD, MSc, FRCPC, Physician/Scientist, University of Ottawa Centre for Transfusion Research, Ottawa Health Research Institute and the Ottawa Hospital
Description
The views of what constitutes good, effective and high- quality platelet products for transfusion vary considerably. This session will provide an overview of what blood bankers, clinicians and researchers consider important features of platelet quality, how these are currently determined and what platelet quality means for the patients. In a changing industry with increasing demands on product safety and supply, the quality of platelets after pathogen reduction and/or beyond 5 days of storage is becoming very important.
-
Discuss clinical measures of platelet quality for prophylactic and therapeutic transfusions with a critical evaluation of current quality tests in view of new trends such as bacterial testing and pathogen reduction.
-
Discuss platelet characteristics used to determine quality of platelet products by blood bankers, clinicians and researchers with consideration of different platelet production methods and platelet substitutes.
-
Evaluate established and emerging methods and technologies to determine platelet quality in vitro and their relevance to clinical transfusion outcome.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.